Researchers from the Netherlands assessed the effect of infliximab on the quality of life in patients with active or fistulizing Crohn's disease.
A total of 65 patients were included in the observational study.
An infusion of 5 mg/kg infliximab was given at week 0 in patients with active disease, and at week 0, 2, and 6 in fistulizing disease.
Changes from baseline in the total and dimensional inflammatory bowel disease (IBD) questionnaire scores were calculated. These were then compared between the patient groups.
Potential predictors of change in the quality of life were identified.
|Predictors of better infliximab response:|
- Inflammatory Crohn's disease
- Young age at diagnosis
| Alimentary Pharmacology & Therapeutics |
In the active disease group, the mean total and dimensional IBD questionnaire scores improved at week 4, compared to baseline.
In the fistulizing group, at week 6, all scores changed from baseline.
The authors found that improvement in the total IBD questionnaire score correlated well with the improvement of the Crohn's disease activity index.
Furthermore, systemic and social scores improved more than bowel and emotional scores.
Inflammatory Crohn's disease and a young age at diagnosis were both predictors for a better response to infliximab therapy.
B. P. J. Van Balkom, of the University Hospital Maastricht, concluded on behalf of colleagues, "Infliximab therapy improves all aspects of the quality of life in patients with Crohn's disease."